Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMV533 in healthy volunteers with induced malaria
NCT05205941Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MMV533 in malaria, sponsored by Medicines for Malaria Venture. Primary endpoints: Activity of Single Oral Doses of MMV533 on Clearance of Plasmodium at 48 hours, Participants With Parasitaemia Below Limit of Quantification at 48 hours and 3 more. Started Mar 2022; status: completed.
02
Drugs
MMV533
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05205941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205941.